LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Search

Protagonist Therapeutics Inc

Closed

SectorHealthcare

61.97 5.25

Overview

Share price change

24h

Current

Min

58.91

Max

62.08

Key metrics

By Trading Economics

Income

-23M

-35M

Sales

-23M

5.5M

P/E

Sector Avg

79.973

35.293

Profit margin

-626.956

Employees

130

EBITDA

-23M

-42M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+23.04% upside

Market Stats

By TradingEconomics

Market Cap

295M

3.6B

Previous open

56.72

Previous close

61.97

News Sentiment

By Acuity

21%

79%

40 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Protagonist Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

10 Mar 2025, 13:59 UTC

Major Market Movers

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

Peer Comparison

Price change

Protagonist Therapeutics Inc Forecast

Price Target

By TipRanks

23.04% upside

12 Months Forecast

Average 72.09 USD  23.04%

High 82 USD

Low 65 USD

Based on 12 Wall Street analysts offering 12 month price targets forProtagonist Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

12

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

43.62 / 44.27Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

40 / 371 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
help-icon Live chat